Immutep are global leaders in the understanding and development of therapeutics that modulate Lymphocyte Activation Gene-3 or “LAG-3” which is a cell surface molecule which plays a vital role in regulating T cells. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases.
The companies objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for the benefit of patients’ health. This is how immunotherapy fights cancer and autoimmune disease.
LAG-3 IMMUNOTHERAPY PRODUCT CANDIDATES
Immutep has three clinical and one pre-clinical LAG-3 related product candidates under development, including two antibodies for modulating immune responses in cancer and autoimmunity, being advanced through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Their lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for various cancer indications.
- Eftilagimod alpha (IMP321) – immunotherapy for cancer
- IMP761 – preclinical immunotherapy for autoimmune disease
- LAG525 or leramilimab (IMP701) – immunotherapy for solid tumors, blood cancer and breast cancer (partnered with Novartis)
- GSK‘781 (IMP731) – immunotherapy in autoimmune diseases (partnered with GSK)
Immutep is listed on the Australian Stock Exchange (IMM) and on the NASDAQ Global Market (IMMP) in the U.S. (ADR’s).
ASX code IMM
Pharmaceuticals- Biotechnology & Life Sciences
Fund manager James McDonald at the Pengana High Conviction Equities Fund provides insight into some of the current opportunities arising for the Fund. In particular, James explains why stock example Immutep is very well placed to benefit from the current...
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to announce it has completed the second tranche of its institutional placement (Placement), details of which were announced to the market on 21 June 2021. The second tranche of the...
Immutep Ltd (ASX:IMM) is a biotechnology company that engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Key points in the...
Immutep CEO Marc Voigt contemplates the frenetic trading in the company’s Nasdaq-listed American Depository Receipts (ADRs) after the patent approval news: the equivalent of 547 million ordinary shares changed hands over the course of the day, more than the...